Literature DB >> 2804914

Establishment of a human malignant meningioma cell line with amplified c-myc oncogene.

K Tanaka1, C Sato, Y Maeda, M Koike, M Matsutani, K Yamada, M Miyaki.   

Abstract

A new cell line (KT21-MG1) has been established from a human malignant meningioma transplanted into nude mice. The cultured cells showed epithelial cell-like morphology and were positive immunohistochemically for vimentin as the original tumor. They have been grown continuously in vitro for more than 2 years. The population doubling time was about 24 hours at the 30th passage. The cells are capable of proliferating in soft agar medium and produced tumors in nude mice, the histologies of which were similar to the original patient-derived tumor. Analysis of cellular oncogenes showed that myc and fps were amplified approximately tenfold and threefold, respectively, in this cell line, whereas N-myc, L-myc, N-ras, K-ras, H-ras, abl, erbB2, Blym, src, raf-1, myb, and sis were not changed significantly. The amplification of myc was accompanied by an enhanced expression. Chromosome studies of cultured cells showed the monosomy of chromosome 22 that has been reported to be a specific abnormality in meningiomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2804914     DOI: 10.1002/1097-0142(19891201)64:11<2243::aid-cncr2820641110>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Dynamin forms a Src kinase-sensitive complex with Cbl and regulates podosomes and osteoclast activity.

Authors:  Angela Bruzzaniti; Lynn Neff; Archana Sanjay; William C Horne; Pietro De Camilli; Roland Baron
Journal:  Mol Biol Cell       Date:  2005-05-04       Impact factor: 4.138

2.  Yes-associated protein 1 is activated and functions as an oncogene in meningiomas.

Authors:  Gilson S Baia; Otavia L Caballero; Brent A Orr; Anita Lal; Janelle S Y Ho; Cynthia Cowdrey; Tarik Tihan; Christian Mawrin; Gregory J Riggins
Journal:  Mol Cancer Res       Date:  2012-05-22       Impact factor: 5.852

3.  Comprehensive pharmacological profiling of neurofibromatosis cell lines.

Authors:  Jianman Guo; Michael R Grovola; Hong Xie; Grace E Coggins; Patrick Duggan; Rukhsana Hasan; Jiale Huang; Danny W Lin; Claire Song; Gabriela M Witek; Simon Berritt; David C Schultz; Jeffrey Field
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

4.  Molecular and translational advances in meningiomas.

Authors:  Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

5.  Re-evaluation of cytostatic therapies for meningiomas in vitro.

Authors:  Annette Wilisch-Neumann; Doreen Pachow; Maren Wallesch; Astrid Petermann; Frank D Böhmer; Elmar Kirches; Christian Mawrin
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-11       Impact factor: 4.553

6.  The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.

Authors:  Katherine Striedinger; Scott R VandenBerg; Gilson S Baia; Michael W McDermott; David H Gutmann; Anita Lal
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

7.  Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Authors:  Sarah S Burns; Elena M Akhmametyeva; Janet L Oblinger; Matthew L Bush; Jie Huang; Volker Senner; Ching-Shih Chen; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

Review 8.  The biology of meningiomas.

Authors:  I E McCutcheon
Journal:  J Neurooncol       Date:  1996-09       Impact factor: 4.130

9.  A microcomputer program for calculating cell population doubling time in vitro and in vivo.

Authors:  J I Zwicker; R T Proffitt; C P Reynolds
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

10.  A genetic strategy to overcome the senescence of primary meningioma cell cultures.

Authors:  Gilson S Baia; Alison L Slocum; Jeanette D Hyer; Anjan Misra; Nouzhan Sehati; Scott R VandenBerg; Burt G Feuerstein; Dennis F Deen; Michael W McDermott; Anita Lal
Journal:  J Neurooncol       Date:  2006-03-23       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.